Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma

Michael H. Storandt, Jennifer J. Gile, Mathias E. Palmer, Tyler J. Zemla, Daniel Ahn, Tanios S. Bekaii-Saab, Zhaohui Jin, Nguyen H. Tran, Amit Mahipal

Research output: Contribution to journalArticlepeer-review

Abstract

(1) Background: Cabozantinib, a multikinase inhibitor, is approved by the Food and Drug Administration (FDA) for the treatment of advanced hepatocellular carcinoma (HCC) following progression on sorafenib. Recently, atezolizumab plus bevacizumab has been approved in the first line setting for advanced HCC and has become the new standard of care. Whether cabozantinib improves outcomes following progression on immunotherapy remains unknown. We describe the clinical outcomes following treatment with immunotherapy in patients with advanced HCC who received cabozantinib. (2) Methods: We conducted a multicentric, retrospective analysis of patients with advanced HCC diagnosed between 2010–2021 at Mayo Clinic in Minnesota, Arizona, and Florida who received cabozantinib. Median overall survival and progression free survival analyses were performed using the Kaplan–Meier method. Adverse events were determined using Common Terminology Criteria for Adverse Events (CTCAE). (3). Results: We identified 26 patients with advanced HCC who received cabozantinib following progression on immunotherapy. Median progression free survival on cabozantinib therapy was 2.1 months (95% CI: 1.3–3.9) and median overall survival from time of cabozantinib initiation was 7.7 months (95% CI: 5.3–14.9). (4) Conclusion: The optimal sequencing of therapy for patients with advanced HCC following progression on immunotherapy remains unknown. Our study demonstrates that patients may benefit from treatment with cabozantinib following progression on immunotherapy.

Original languageEnglish (US)
Article number5173
JournalCancers
Volume14
Issue number21
DOIs
StatePublished - Nov 2022

Keywords

  • cabozantinib
  • hepatocellular cancer
  • immunotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma'. Together they form a unique fingerprint.

Cite this